Goldan Keith A. sold $22K of SNDX
Goldan Keith A. (Chief Financial Officer) sold 1,177 shares of Syndax Pharmaceuticals Inc (SNDX) at $18.99 on 2026-06-01.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale amount, date, and price, which can influence short-term sentiment but does not constitute new operational or financial guidance.
Market read
Traders may monitor for follow-on insider activity, but this specific transaction is small and not linked to new company fundamentals in the text.
What to watch
The article provides only the sale details and post-transaction holdings; it does not include context like prior grants, compensation timing, or whether other insiders sold/bought around the same period.
Background
The filing is an SEC Form 4 insider transaction for Syndax Pharmaceuticals, reported by the CFO.
Ticker impact
Syndax CFO Goldan Keith A. sold 1,177 shares on 2026-06-01 at $18.99, totaling about $22.35K, per Form 4.
Low near-term impact; any reaction is likely limited to sentiment and should fade unless more selling or new fundamentals emerge.
The disclosure is a small dollar amount relative to typical company market caps, and it is not tied to a corporate event, guidance, or regulatory action in the text.
Market effects
No sector-wide signal is provided; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative information.
Key entities
- issuerSyndax Pharmaceuticals Inc
Subject of the Form 4 insider transaction disclosure.
- insiderGoldan Keith A.
CFO who executed the open-market sale.
